Mammalian sirtuin 1 (SIRT1) has connected to an ever widening circle of activities that encompass cellular stress resistance, energy metabolism and tumorigenesis. However, underlying mechanisms leading to oncogenic SIRT1 overexpression are less understood. In this study, we identified SIRT1 regulatory microRNA (miRNA) and its function in hepatocellular carcinoma (HCC). Aberrant SIRT1 overexpression was demonstrated in a subset of human HCCs. SIRT1 knockdown suppressed HCC cell growth by transcriptional deregulation of cell cycle proteins. This led to hypophosphorylation of pRb, which inactivated E2F/DP1 target gene transcription, and thereby caused significant increase of HCC cells to remain in the G1/S phase. A comprehensive miRNA profiling analysis indentified five putative endogenous miRNAs that are significantly downregulated in HCC. Ectopic expression of miRNA mimics evidenced miR-29c to suppress SIRT1 in HCC cells. Notably, ectopic miR-29c expression repressed cancer cell growth and proliferation, and it recapitulated SIRT1 knockdown effects in HCC cells. In addition, miR-29c expression was downregulated in a large cohort of HCC patients, and low expression of miR-29c was significantly associated with poor prognosis of HCC patients. Taken together, we demonstrated that miR-29c suppresses oncogenic SIRT1 by way of binding to 3 0 -untranslated region of SIRT1 mRNA causing translational inhibition in liver cancer cells. The loss or suppression of miR-29c may cause aberrant SIRT1 overexpression and promotes liver tumorigenesis. Overall, we suggest that miR-29c functions as a tumor suppressor by regulating abnormal SIRT1 activity in liver.
INTRODUCTION
Liver cancer is the fifth most common cancer and the second most common cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 70-85% of all liver cancers. 1 Several environmental factors, including hepatitis B and C viral infections, aflatoxin B1 and alcohol, are the main causes of HCC, but no universally curative therapy for HCC has been established. 1 Many studies have suggested that the loss of several tumor suppressors and the aberrant regulation of cellular growth signaling pathways, such as the ERK/MAPK pathway and Wnt/b-catenin pathway, are involved in HCC tumorigenesis, 2 but the molecular pathogenesis of HCC remains poorly understood.
Sirtuins are NAD þ -dependent deacetylases that target histone and non-histone proteins and are major factors in the response to oxidative, metabolic and genotoxic stresses. The importance of sirtuins is demonstrated by their role in several major human pathologic conditions, including cancer, diabetes, cardiovascular disease and neurodegenerative disease. 3 Mammals express seven sirtuins (denoted SIRT1-7) that have considerably different functions and catalytic activities. SIRT1 is the best-characterized sirtuin, and possesses a large number of substrates, including p53, Myogenic differentiation 1 (MyoD), Forkhead box O3 (FOXO3), Nuclear factor kB (NF-kB) and others. 4 SIRT1 is involved in many cellular pathways, such as cellular survival, the cellular stress response, energy metabolism and apoptosis. The overexpression of SIRT1 has been reported in a variety of human cancers, including prostate cancer, ovarian cancer, gastric cancer and colorectal cancer. The silencing of SIRT1 in cancer cell lines has been shown to suppress cancer cell growth and lead to cell cycle arrest and apoptosis. [5] [6] [7] [8] Recently, it has been suggested that SIRT1 regulation is aberrantly overexpressed in a subset of human HCCs, and this impaired regulation has a pivotal role in telomere maintenance and tumor growth. 9 However, underlying mechanisms leading to oncogenic SIRT1 overexpression are less understood.
MicroRNAs (miRNAs) are small non-coding RNAs (21-25 nucleotides) that provoke mRNA degradation or the blockade of mRNA translation by binding to the 3 0 -untranslated region (3 0 UTR) of target mRNAs. 10 Both the loss and gain of miRNA function contributes to cancer development through the upregulation of oncogenes and silencing of tumor suppressor genes, respectively. In HCC, aberrant expressions of miRNAs, such as miR-21, miR-29 and miR-221, have been reported to regulate tumor cell growth, apoptosis, migration and invasion by targeting proteins involved in those cellular pathways. [11] [12] [13] However, no miRNAs that selectively regulate SIRT1 in HCC have been identified.
In this study, we studied SIRT1 expression in a subset of HCCs. We demonstrated that SIRT1 overexpression potently stimulated HCC cell growth via transcriptional inactivation of p21 Cip1 , p27 Kip1 , p15 INK4B and activation of CDK2, CDK6, cyclin D3 and cyclin D1. In addition, we performed miRNA expression profiling analysis to investigate deregulated miRNAs in HCC, and identified five 1 miRNAs targeting SIRT1 that are significantly downregulated in HCC. Additional research evidenced that miR-29c was an endogenous regulator of SIRT1 in HCC cells. Notably, miR-29c expression was significantly downregulated in a large cohort of HCC patients, and that lower expression of miR-29c was associated with a poor prognosis in HCC. Our data demonstrated that miR29c functions as tumor suppressor by direct suppressing oncogenic SIRT1 in normal liver cells, suggest that miR-29c has a potential therapeutic value for the treatment of liver cancer.
RESULTS

SIRT1 is aberrantly regulated in HCC and its inactivation causes growth inhibition
To validate the previously observed pattern of aberrant SIRT1 regulation in HCC in Korean patients, we investigated SIRT1 expression of 50 HCCs with corresponding non-cancerous liver tissues by western blot analysis. SIRT1 was markedly upregulated in 35 out of 50 (70%) HCCs compared with adjacent noncancerous liver tissue (Figures 1a and b) . Then we recapitulated SIRT1 gene expression in the large cohort of HCC patients that available from the National Center for Biotechnology Information (NCBI) and Gene Expression Omnibus (GEO) database (accession numbers: GSE14520 and GSE22058). Consistent with a previous report, 9 SIRT1 mRNA levels were not significantly different between HCC and non-tumor in these two different HCC cohorts (Figures 1c and d) . Note that there was no significant correlation of SIRT1 expression with multistep histopathological grades of HCC in both western blot analysis of 50 HCC tissues and immunohistochemical analysis of HCC tissue microarray containing 47 matched pairs of HCC and corresponding non-cancerous liver tissues (Supplementary Tables 1 and 2 , Supplementary  Figures 1a and b) . These data support that SIRT1 protein is overexpressed in overt HCC, but the aberrant regulation of SIRT1 occurs at a post-transcriptional level.
Next, to investigate biological functions of SIRT1 in hepatocellular malignant proliferation and transformation, we attempted SIRT1 knockdown using RNA interference and studied in the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenytetrazolium bromide (MTT) assay for the measurement of cell growth rate, and bromodeoxyuridine (BrdU) incorporation and clonogenic assays for the measurement of cell proliferation rate of three different liver cancer cell lines, SNU-182, HepG2 and Hep3B, respectively. SIRT1 knockdown resulted in a significant reduction in SIRT1 protein expression and in reduced growth and proliferation rates of these three different liver cancer cell lines (Figures 2a and b,  Supplementary Figure 2a) . Note that the inhibition of SIRT1 enzyme activity by sirtinol (20 mM) treatment, a specific SIRT1 deacetylase inhibitor, 14 caused significant growth impairment without effecting SIRT1 protein levels indicating requirement of deacetylase enzyme activity for growth stimulation of SIRT1 in HCC (Figure 2c, Supplementary Figure 2b ). This anti-growth effect could be partially explained by the disruption of cell growth regulation, such as cell cycle arrest, cellular senescence or apoptosis, on SIRT1 targeting. Thus, we next explored the effects of SIRT1 knockdown on cell cycle regulation. Flow cytometric cell The patient number was rearranged according to the SIRT1 expression level. (c, d) Analysis of microarray data from the Gene Expression Omnibus (GEO) database. GSE data set of accession numbers GSE14520 (c) and GSE22058 (d) showed that SIRT1 mRNA expression was not significantly different between HCC and non-tumor groups (GSE14520, P ¼ 0.1596; GSE22058, P ¼ 0.0708). NS, non-significant. Figure 3a ).
To better understand the biological roles of SIRT1 in cell cycle progression, SIRT1 knockdown was attempted by three different siRNAs targeting SIRT1 and studied in the western blot analysis for cell cycle component. All three different siRNAs targeting SIRT1 exhibited the suppression of SIRT1, and SIRT1 inactivation was confirmed by detecting elevated level of acetylated histone H4 in SNU-182 cells. This SIRT1 knockdown elicited induction of p21 Cip1 , Cip1 and p27 Kip1 expression, and suppressed cyclin D1, D3, CDK6 and CDK2 expression among cell cycle regulators ( Figure 3d ). In general, the activated CDK/cyclin complex can cause hyperphosphorylation of pRb, which then loses its tumorsuppressor activity and allows for increased E2F/DP1 transcriptional activity. As we expected, SIRT1 knockdown led to hypophosphorylation of pRb and the downregulation of several downstream target genes of E2F/DP1 transcription factor such as E2F1, PCNA, cyclin A and c-Myc (Figure 3d ). These results strongly suggested that SIRT1 hyperactivity modulates transcription of cell cycle proteins to foster the transition from G1 to S phase in liver cancer cells.
Identification of endogenous miRNAs to control SIRT1 regulation in liver cancer
The fact that SIRT1 is upregulated at the post-transcriptional level in HCC led us to hypothesize that normal SIRT1 expression is balanced by endogenous miRNA, which selectively controls SIRT1 mRNA translation in normal hepatic liver cells. Based on this mechanism, the loss or suppression of miRNA targeting SIRT1 could contribute to the aberrant overexpression of SIRT1 and lead to hepatocelluar malignant proliferation and transformation. Note that Dicer, a miRNA-processing enzyme, knockdown elevated SIRT1 protein expression in both Hep3B and SNU-182 HCC cells (Figure 4a ). This result indicates that there exist miRNAs regulating endogenous SIRT1 expression in liver cancer cells. Thus, to identify endogenous miRNAs that downregulated in HCC, we performed a comprehensive miRNA expression analysis in a subset of HCCs. Unsupervised hierarchical clustering analysis of 510 miRNAs that were selected by minimum filtering criteria of 1371 miRNAs of 8 normal liver tissues and 16 HCCs resulted in two distinct clusters within dendrogram and suggested characteristic miRNA signature associated with HCC tumorigenesis (Figure 4b ). Then a target prediction program, miRanda (http://www.microrna.org), was used to predict and identify miRNAs that possibly target the endogenous SIRT1 in HCC. From this, we identified five miRNAs (miR-29c, 141, 145, 181a and 199a-5p) that are significantly downregulated in HCC (Figure 4c ).
To determine whether SIRT1 was selectively regulated by these miRNAs via direct interaction with the 3 0 UTR of the SIRT1 gene, we cloned the 3 0 UTR of SIRT1 into a reporter vector to generate psiCHECK2-SIRT1_3 0 UTR wild type (psiCHECK2-SIRT1-wt). Then this vector was co-transfected in SNU-182 cells with the five selected miRNAs. We found that miR-29c and miR-141 suppressed reporter gene activity in SNU-182 cells, whereas miR-145, miR-181a and miR-199a-5p had no effect. This indicated that miR-29c and miR-141 are able to regulate SIRT1 expression in liver cancer cells in vitro (Figure 4d ). Next we assessed whether ectopic expression of these five miRNAs mimicked the effects of SIRT1 inactivation by siRNA directed against SIRT1 in liver cancer cells. Consistent with the results of the luciferase assays, both miR-29c and miR-141 suppressed endogenous SIRT1 expression, similar to as observed with SIRT1 siRNA in SNU-182 cells (Figure 4e ). However, we found that only miR-29c was able to induce p21
Cip1 in SNU-182 cells. These results suggested that miR-29c is a specific regulator of SIRT1 in liver. Moreover, to verify that the miR-29c sequence was specific for SIRT1, we also cloned the 3 0 UTR of random mutation sequences of the SIRT1 gene to generate a mutant-type (psiCHECK2-SIRT1-mt) reporter vector, and the results of dualluciferase reporter assays of psiCHECK2-SIRT1-wt plasmid with miR-29c was compared with that of psiCHECK2-SIRT1-mt (Figure 4f ).
MiR-29c functions as tumor suppressor by direct inhibiting oncogenic SIRT1 in liver As we observed that miR-29c was significantly downregulated in HCC and that ectopic expression of miR-29c elicited SIRT1 inactivation in HCC cells, we investigated the endogenous expression of miR-29c in various liver-derived cell lines including THLE-2 and THLE-3, immortalized normal hepatic liver cell lines by quantitative real-time-PCR (qRT-PCR) analysis. As we expected, most of liver cancer cell lines exhibited significant low level of endogenous miR-29c expression as compared with normal hepatic cells, whereas certain liver cancer cell lines, such as SNU-354 or SNU-368, expressed relatively high level of endogenous miR-29c expression, similar to normal hepatic cells (Figure 5a , lower panel). To clarify whether endogenous miR-29c expression reflects SIRT1 protein expression, we measured endogenous SIRT1 protein level in same cell lines. Notably, expression of SIRT1 in SNU-354 and SNU-368 cells was almost non-detectable, similar to normal hepatic cells, whereas SIRT1 expression was highly elevated in HepG2, Hep3B and SNU-182 cells (Figure 5a , upper panel). We then observed that the ectopic expression of miR-29c significantly suppressed SIRT1 expression in HepG2, Hep3B and SNU-182 cells, similar to as observed with SIRT1 siRNA (Figure 5b ). On the other hand, suppression of SIRT1 protein expression was rescued by ectopic antisense miR-29c (anti-miR-29c) transfection in SNU-368 cells (Figure 5c ). Note that ectopic expression of miR29c caused a significant growth inhibition in SNU-182 cells as determined by both MTT and BrdU assays (Figure 5d,  Supplementary Figure 3) .
Although we showed that ectopic miR-29c elicited inhibition of cellular growth and proliferation of liver cancer cells, it is necessary to prove that miR-29c directly targets and suppresses SIRT1 protein expression through the binding of 3 0 UTR of SIRT1 gene. To this end, we performed the rescue experiment by introducing SIRT1-expressing plasmid (pcDNA3.1-SIRT1-His) or Mock (empty vector) in the presence or absence of ectopic miR-29c expression in liver cancer cells. Ectopic miR-29c expression attenuated endogenous SIRT1 protein expression, thereby led to the suppression of cellular growth and proliferation in both MTT and BrdU assay (Figures 6a-c) . Importantly, this anti-growth effect of ectopic miR-29c was attenuated by co-transfection of SIRT1-expressing plasmid. Note that SIRT1-expressing plasmid does not contain 3 0 UTR of SIRT1 gene and therefore, only endogenous SIRT1 can be suppressed by ectopic miR-29c. Indeed miR-29c suppresses endogenous SIRT1 protein expression, but it does not suppress the ectopic SIRT1 protein expression (SIRT-His, upper band of immunoblot with anti-SIRT1 antibody in Figure 6a ). Moreover, anti-growth effect of miR-29c was significantly attenuated by ectopic SIRT1-His expression. This result clarifies that miR-29c directly targets and suppresses SIRT1 through the inhibition of SIRT1 mRNA translation in liver. In addition, when we assessed the effect of miR-29c on cell cycle distribution, we observed that miR-29c induced G1 arrest, similar to as observed with SIRT1 siRNA (Figure 6d) . We then examined cell cycle regulators of the G1/S transition in miR-29c-expressing cells by western blot analysis. Ectopic expression of miR-29c selectively induced p15 INK4B and p21 Cip1 , and simultaneously suppressed the expression CDK6 and CDK2 among G/S cell cycle regulators. This led to hypophosphorylation of pRb, which inactivated E2F/DP1 target gene transcription such as cyclin A and E2F1 (Figure 6f ).
To generalize our findings, we recapitulated miR-29c expression in a large cohort of HCC patients available from the NCBI and GEO database (accession numbers: GSE10694 and GSE21362), and data were shown as scatter plot (Figures 7a and b) . MiR-29c expression was significantly downregulated in these two different HCC cohorts. In addition, Kaplan-Meier survival curves of patients with HCC indicated that the 5-year overall survival rate of HCC patients with low miR-29c expression was significantly lower than that of INK4B and p21 Cip1 were evaluated to confirm the cellular response to SIRT1 inhibition. GAPDH was used as the loading control. (f ) Luciferase reporter assay. Wild-type (3 0 UTR WT) and mutant SIRT1 3 0 UTR (3 0 UTR Mut) constructs were inserted into psiCHECK-2 plasmid and transfected with miR-29c into SNU-182 cells (mean ± s.d., n ¼ 3, *Po0.05). NC, negative control miRNA; NS, non-significant. (Figure 7d ). In addition, to evidence clinical significance of these findings in vivo, we investigated whether SIRT1 protein expression has inverse correlation with miR-29c expression in a subset of human HCCs. To this end, we performed qRT-PCR analysis for 10 paired HCCs, of which SIRT1 is significantly overexpressed in HCC, as observed by western blot analysis of the results in Figure 1a . As expected, miR-29c was remarkably downregulated in all tested HCCs compared with corresponding non-tumor, and appeared to be inversely correlated with SIRT1 expression (Figures 7e and f) . In contrast, when we assessed miR-29c expression of 10 paired HCCs, of which show no difference in SIRT1 expression, 6 out of 10 tested HCCs displayed no difference in miR-29c expression (Supplementary Figure 4) . Overall, these results demonstrate that miR-29c is a direct regulator of endogenous SIRT1 and may function as a tumor suppressor by regulating abnormal activity of SIRT1 in human HCC.
DISCUSSION
Despite extensive studies for several decades, the role of SIRT1 in human cancer remains controversial. Increased SIRT1 expression has been found to reduce tumor formation in a mouse model of colon tumor, 15 whereas SIRT1 mutant mice have exhibited increased DNA instability and are more susceptible to tumor development. 16 Reduced levels of SIRT1 mRNA and proteins are observed in breast tumors when compared with normal tissue. 16 Similarly, SIRT1 may suppress colon cancer cell growth and in vivo tumor formation. 17 Intriguingly, however, SIRT1 overexpression is found in prostate, 5 ovarian, 6 gastric 7 and colorectal cancers, 8 suggesting a role in tumorigenesis. Therefore, the function of SIRT1 may be tumor-type specific and may also depend on the stage of tumorigenesis being assessed.
In liver cancer, especially in HCC, Wang et al. 16 used pooled microarray data from HCC samples to suggest that SIRT1 mRNA is expressed at comparable levels in both malignant and benign tissues. They further concluded that SIRT1 protein expression is reduced in HCC on the basis of one paired HCC specimen. 16 In contrast, Chen et al. 9 have demonstrated that SIRT1 protein was overexpressed by a post-transcriptional mechanism in a subset of HCC. They have also shown that SIRT1 expression is low in normal and premalignant livers, and its overexpression is closely associated with poorly differentiated histology. 9 In agreement with their results, our study confirmed that SIRT1 protein was overexpressed in a subset of patients with HCC, whereas SIRT1 mRNA levels did not differ between HCC and non-tumoral tissues in a large cohort of HCC patients. Furthermore, we demonstrated that SIRT1 inactivation suppressed in vitro cell growth and proliferation of liver cancer cells (Figure 2 ). Many previous reports have suggested that histone deacetylase (HDAC)-mediated gene suppression can cause uncontrolled cell growth because HDACs repress the transcription of cyclin-dependent kinase inhibitors, allowing continued cellular proliferation. 18, 19 Our results demonstrated that SIRT1 hyperactivity suppresses cell cycle checkpoints, such as p15 INK4B , p21 Cip1 and p27 Kip1 , and modulates activity of cyclins to foster G1/S transition of liver cancer cells (Figures 3a and d) . These results clearly support our suggestion of oncogenic SIRT1 in hepatocellular malignant proliferation and transformation. However, regulation of SIRT1 activity or expression leading to oncogenic SIRT1 overexpression is not studied yet.
Recent studies have suggested that SIRT1 expression is regulated by miRNAs in various tissues, and miRNAs regulating SIRT1 are involved in many cellular pathways, including mouse embryonic stem cell differentiation, apoptosis, senescence and hypoxia. For instance, during mouse embryonic stem cell differentiation differentiation, miR-9, miR-204, miR-199b and miR-135a suppressed SIRT1 expression. 20 These findings led us to hypothesize that SIRT1 overexpression at the posttranscriptional level may be induced by the loss or suppression of a miRNA that selectively targets SIRT1. The induction of SIRT1 protein by Dicer knockdown helped us to identify endogenous miRNAs that blocked SIRT1 mRNA translation in HCC cells. However, it may not be convincing that the Dicer knockdown causes the induction of SIRT1 protein, because miR-29c expression is already markedly downregulated in non-transfected cells. This question can be explained by recent publication. 21 They have shown that proteins consist of polycomb group complex 1, such as RING2 and BMI1, were induced by siRNA-mediated Dicer knockdown in DU145 and BT-549 prostate cancer cells. Note that miRNAs targeting those molecules, miR-200b and miR-200c, were also significantly downregulated in DU145 cells compared with benign cell lines. 21 Importantly, they also showed that miR-200b Figure 6 . miR-29c functions as tumor suppressor by inhibiting SIRT1 mRNA translation in liver. (a-c) The rescue experiment was performed by introducing SIRT1-expressing plasmid (pcDNA3.1-SIRT1-His) or Mock (empty vector, pcDNA3.1-His) in the presence or absence of ectopic miR-29c expression in SNU-182 cell lines. Cells were transfected with miR-29c mimic (miR-29c) and 3 0 UTR-negative SIRT1 expression plasmid (pcDNA3.1-SIRT1-His). NC, negative control miRNA. (a) Western blot analysis. After 48 h of transfection, endogenous SIRT1, not ectopically expressed SIRT1 (SIRT1-His), was suppressed by ectopic miR-29c transfection. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the loading control. (b) MTT assay. After transfection, cell growth was measured for 72 h. Anti-growth effect of ectopic miR-29c was attenuated by co-transfection of SIRT1-expressing plasmid (**Po0.01; ***Po0.001). (c) BrdU incorporation assay. Suppressed cell proliferation rate by miR-29c was rescued by ectopic SIRT1 expression (SIRT1-His) at 48 h post-transfection (***Po0.001). (d) Fluorescence-activated cell sorting analysis. Cell cycle distribution was determined by propidium iodide (PI) staining in SNU-182 cells at 48 h after transfection (mean ± s.d., n ¼ 3, *Po0.05). (e) The effects of miR-29c on cell cycle proteins in the G1/S transition were determined by western blot analysis. GAPDH was used as the loading control.
miR-29c regulates SIRT1 expression in liver HJ Bae et al and miR-200c were downregulated in prostate cancer progression, similar to as observed with SIRT1 and miR-29c in liver cancer of our study. Although they did not explain how Dicer knockdown induces these proteins, which already overexpressed in nontransfected cells, it may be possible that targeted disruption of Dicer confers complete inactivation of miRNA-processing machinery in cells, and thereby it elicits the clearance of the endogenous miRNAs that already downregulated in these cells, and consequently, induces targeted proteins. Furthermore, when we co-transfected Dicer siRNA with miR-29 mimics or miR-29c precursor (pre-miR-29c)-expressing plasmid to SNU-182 liver cancer cells, we observed that elevated SIRT1 expression was remarkably attenuated by miR-29c mimic transfection, whereas pre-miR-29c was not effective (Supplementary Figure 5) . These data show that miRNA-processing machinery is required for miR29c as endogenous regulator for oncogenic SIRT1 in liver. Previous studies have suggested that the miR-29 family has an important role in the regulation of apoptosis and molecular etiology of HCC. 12 The human miR-29 family has three mature members, miR-29a, miR-29b and miR-29c. The miR-29 family members share a common seed sequence and have been predicted to target largely overlapping sets of genes. However, miR-29 family members exhibit differential regulation in several circumstances and different subcellular distributions, suggesting that their functional roles may be unique. 22 In recent studies, miR-29 family members have been shown to be involved in tumorigenesis through the direct targeting of a wide variety of proteins. For instance, miR-29 family proteins induced aberrant methylation by inhibiting DNA methyltransferases 3A and 3B, which suppressed tumor formation. 3 In HCC, it has been demonstrated that miR-29s act as tumor-suppressor miRNAs via targeting Bcl-2 and Mcl-1. Also, it has been shown that downregulation of miR-29b was closely related to poor prognosis in HCC. 12 We have shown that ectopic miR-29c expression attenuated endogenous SIRT1 protein expression, thereby led to the suppression of cellular growth and proliferation in both MTT and BrdU assay. But, this rescue of phenotype seem to be partial (Figures 6b and c) , and there is possibility that miR-29c may act as tumor suppressor by targeting not only SIRT1 but also targeting other genes. Therefore, the effect that the partial rescue by SIRT1 leaves open possibility that additional targets of miR-29c may also contribute in hepatocarcinogenesis. In addition, our results from large-scale miRNA expression profiling analyses of HCC and public phenomiR database analyses (http://mips.helmholtz-muenchen. de/phenomir) demonstrated that only miR-29c was significantly downregulated in a large cohort of patients with HCC. Also, the downregulation of miR-29c was an independent prognostic factor among miR-29 family members in HCC. For instance, miR-29a was downregulated in our miRNA profiling analyses (GSE39678). However, other large HCC cohort data showed no significant difference between miR-29a expression in HCCs and benign tissues (GSE10694 and GSE21362). Conversely, a high level of expression of miR-29a was associated with a poor prognosis in patients with HCC (Supplementary Figure 6) . We also found that miR-29b expression was not downregulated in a large cohort of HCC patients, and we found that a low level of miR-29b expression was not significantly associated with poor prognosis in patients with HCC (Supplementary Figure 7) .
Overall, we suggest evidence that miR-29c functions as a tumor suppressor by inhibiting SIRT1 hyperactivity in liver. The expression of miR-29c was downregulated in overt HCC and significantly associated with a poor prognosis in patients with HCC. We found miR-29c regulates SIRT1 expression in liver HJ Bae et al that the ectopic expression of miR-29c recovered the activity of negative cell cycle regulators while suppressing cyclins and CDKs, and thereby inhibited in vitro tumor growth and proliferation in HCC cells. These findings define a central role for miR-29c in HCC tumorigenesis and suggest that miR-29c has a potential therapeutic value for the treatment of liver cancer. Transfections and treatments siRNAs and miRNA mimics were synthesized by Genolution (Seoul). Negative control RNA duplexes were purchased from Ambion (Austin, TXUSA). The sequences of the RNA duplexes are indicated in Supplementary Table 3 . Transfections were performed with Lipofectamine RNAiMAX reagents (Invitrogen). Peptide nucleic acid-modified miRNA inhibitors were purchased from PANAGENE (Daejon, Korea). Cells were treated with 20 mM of sirtinol (Tocris Biosciences, Ellisville, MO, USA) to inhibit endogenous SIRT1 activity.
MATERIALS AND METHODS
Western blot analysis
Western blot analysis was performed as described elsewhere 23, 24 with the following antibodies: anti-SIRT1, -GAPDH, -CDK2, -CDK6 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-acetyl histone H4 (Upstate, Lake Placid, NY, USA), anti-p21 
MTT assay
Cells were seeded in a six-well plate at 30-80% confluency. After transfection or treatment, cells were incubated with 0.5 mg/ml of MTT for 1 h at 37 1C every 24 h. The formazan crystal was dissolved with dimethyl sulfoxide and absorbances were read at 570 nm by VICTOR3 multilabel counters (Perkin-Elmer, Waltham, MA, USA).
BrdU incorporation assay
Cells were seeded in a 24-well plate and were transfected with siRNAs/ miRNAs or treated with sirtinol for 72 h. The assay was performed with BrdU cell proliferation assay kit (Millipore, Billerica, MA, USA) according to the manufacturer's protocol.
Clonogenic growth assay
Cells were transfected with SIRT1 siRNA in 60-mm culture dishes. After 24 h, 4 Â 10 3 cells were transferred to six-well plates and incubated for 4 weeks. Then, cells were rinsed with PBS and fixed with 1% formaldehyde for 30 min at room temperature. Fixed cells were stained with 0.5% crystal violet. Colonies were counted using a clono-counter program as previously described. 25 Cell cycle analysis To determine cell cycle distribution, cells were plated in 60-mm dishes and transfected with small RNA duplexes. After transfection, cells were collected by trypsinization, fixed in 70% ethanol, washed in PBS, resuspended in 200 ml of PBS containing 1 mg/ml RNase, 0.05% Triton X-100 and 50 mg/ml propidium iodide (BD Biosciences, San Jose, CA, USA), incubated in the dark for 30 min at 37 1C, and analyzed using flow cytometry. The data were analyzed using CellQuest Pro software (BD Biosciences).
Differential miRNA expression profiling miRNA expression profiling of 8 normal liver samples and 16 HCC tissue samples was performed as previously described. 24 After data normalization and filtering, 510 miRNAs were used for unsupervised hierarchical clustering. Cluster and TreeView programs (Stanford University, CA, USA) were used for visualization. Primary data are available from the NCBI GEO public database (accession number: GSE39678).
SIRT1 3
0 UTR constructs A SIRT1 3 0 UTR was amplified from liver cancer cell line cDNAs and cloned into the XhoI/NotI site of a psiCHECK-2 vector (Promega, Madison, WI, USA). For mutagenesis of the miR-29c-binding site, a QuickChange site-directed Mutagenesis Kit (Agilent Technologies, Palo Alto, CA, USA) was used according to the manufacturer's instructions. Primers are indicated in Supplementary Table 3 .
Luciferase activity assay Cells were seeded into 12-well plates one day before transfection, and then co-transfected with 200 ng of psiCHECK-2 vectors, which harbored SIRT1 3 0 UTR wild-type or mutant constructs, and 100 nM of miRNAs. After 72 h, luciferase activity was measured with a dual-luciferase assay kit (Promega). Renilla luciferase activity was normalized to firefly luciferase activity.
qRT-PCR
Total RNA was isolated from frozen tissues and cell lines with Qiazol reagent and miRNeasy mini kit (Qiagen, Valencia, CA, USA). For synthesis of cDNAs specific to miR-29c, a TaqMan miRNA reverse transcription kit (Applied Biosystems, Carlsbad, CA) was used. The qRT-PCR reactions were performed with iQ SYBR Green supermix (Bio-Rad, Hercules, CA). Expression levels of U6 snRNA was used as loading control. The PCR was monitored in real-time using an iQ-5 (Bio-Rad) that allowed determination of the threshold cycle (Ct) at the time exponential amplification of the PCR products began. The average Ct, from triplicate assays, was used for further calculations. Primers are indicated in Supplementary Table 3 . Results are expressed as the mean value of triplicate experiments. Relative expression levels were normalized to controls ¼ 2 -(Target Ct-Control Ct) .
Statistical analyses
All experiments were performed at least three times, and all samples were analyzed in triplicate. Results are presented as mean ± s.d. The statistical difference between experimental groups was assessed by unpaired Student's t-tests using Graphpad 4.0 software.
